Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...

In other words, this healthcare stock looks risky right now and is, at this point, unlikely to make investors rich over the ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

Biogen Inc (NASDAQ:BIIB) reflects mixed sentiment as Nasdaq composite trends highlight biotech sector dynamics.

Biogen (BIIB) stock gains as Piper Sandler upgrades the company, citing positives in the company’s recent deal to acquire eye ...

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

Biogen, TE Connectivity and ZTO Express gain attention as broker upgrades and solid earnings growth position them for potential upside in a record-high market.

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis ...

Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week: Qualcomm ( ...

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will ...